Shanghai Zhimeng Biopharma, Inc.
Shanghai Zhimeng Biopharma, Inc.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT07082192 | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder | Recruiting | Phase 2 | 2026-09-22 | NCT06612775 | |
| An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy | brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder | Recruiting | Phase 2 | 2025-11-20 | NCT07238868 | |
| A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Not yet recruiting | Phase 3 | 2025-08-03 | NCT07095855 |